Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of exenatide plus metformin vs. premixed human insulin aspart plus metformin on glycemic control and hypoglycemia in patients with inadequate control of type 2 diabetes on oral antidiabetic treatment.

Trial Profile

Effect of exenatide plus metformin vs. premixed human insulin aspart plus metformin on glycemic control and hypoglycemia in patients with inadequate control of type 2 diabetes on oral antidiabetic treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Exenatide (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Jun 2010 Results of the metformin only pretreatment arm were presented at the 70th Scientific Sessions of the American Diabetes Association.
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top